Glutathione Peptide Protocol & Dosing

What it is

Glutathione is a tripeptide made from glutamate, cysteine, and glycine. It is the main intracellular antioxidant. IV use belongs in a medical setting. IM or SQ use stays research-based.

Evidence boundary

Investigational with mixed human evidence.

Trial evidence

PMID 41416233 — Systematic Review of the Efficacy and Safety of Topical Glutathione in Dermatology.
PMID 39444151 — Glutathione as a skin-lightening agent and in melasma: a systematic review.
PMID 41977262 — N-Acetylcysteine in Neurological Disorders: A Systematic Review of Clinical and Translational Evidence Across Seven Disorders.

Preparation and measurement

Reconstitution: 1500 mg vial + 5 mL BAC = 300 mg/mL.

Concentration matches.

Reference schedule

Reference schedule
Route	Dose	Draw / measure	Frequency	Weekly total
Topical/dermatology	Product-specific	Product-specific	As directed	Not fixed
Lower-dose research IM/SQ	100–200 mg	33.3–66.7 U (0.333–0.667 mL)	1–2× weekly	100–400 mg/week
IV setting	600–1500 mg	—	only	only

Topical/dermatology

Dose: Product-specific
Draw / measure: Product-specific
Frequency: As directed
Weekly total: Not fixed

Lower-dose research IM/SQ

Dose: 100–200 mg
Draw / measure: 33.3–66.7 U (0.333–0.667 mL)
Frequency: 1–2× weekly
Weekly total: 100–400 mg/week

IV setting

Dose: 600–1500 mg
Draw / measure: —
Frequency: only
Weekly total: only

Weekly totals apply only during the active phase. The IM/SQ rows are research notes, not a validated standard.

Titration rules

100 mg is the cautious research start.
150 mg is the middle step.
200 mg is the higher collected research step.
Keep IV work in a clinic.
Oxidative stress / antioxidant intent
Tolerability
Injection-site reactions
Flushing or nausea during dosing
Whether the route is being treated as a finished standard

Practical rules

Keep IV use in a clinic.
Do not treat SQ dosing as a validated standard.
Rotate sites for IM/SQ use.
Pair with sleep and diet rather than expecting it to carry the whole plan.